Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Pharmacokinetics of Evacetrapib in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Evacetrapib (Primary) ; Omeprazole (Primary)
- Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 10 Jun 2016 Primary endpoint has not been met. (Pharmacokinetics (PK): Time of Maximum Observed Concentration (tmax) of Evacetrapib), as per results published in the Pharmacotherapy.
- 10 Jun 2016 Results (n = 34) published in the Pharmacotherapy.
- 02 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.